View Valuation4DMedical 将来の成長Future 基準チェック /264DMedical利益と収益がそれぞれ年間84.3%と85.3%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に-4.5% 86.5%なると予測されています。主要情報84.3%収益成長率86.50%EPS成長率Healthcare Services 収益成長22.9%収益成長率85.3%将来の株主資本利益率-4.54%アナリストカバレッジLow最終更新日03 May 2026今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Apr 014DMedical Limited has completed a Follow-on Equity Offering in the amount of AUD 83.000002 million.4DMedical Limited has completed a Follow-on Equity Offering in the amount of AUD 83.000002 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 14,067,797 Price\Range: AUD 5.9 Discount Per Security: AUD 0.236 Transaction Features: Subsequent Direct Listingお知らせ • Mar 304Dmedical Limited Announces Commercial Launch of CT:VQ Imaging Technology in European Union4DMedical Limited announced that its latest imaging technology, CT:VQ has received CE Mark certification for commercial use in the European Union. 4DMedical will quickly launch commercial deployment of CT:VQ across one of the world's largest respiratory imaging markets. CT:VQ is the world's first and only non-contrast, ventilation-perfusion imaging technology, providing quantitative functional lung insights from routine non-contrast CT scans without the need for radiotracers or specialised nuclear medicine infrastructure. Pulmonary disease is fundamentally functional—defined by abnormalities in ventilation and perfusion—yet most routine imaging available to radiologists and pulmonologists remains purely structural. CT:VQ bridges that gap by generating ventilation and perfusion maps allowing clinicians to visualize regional lung function with the anatomical clarity of CT. For large medical institutions, CT:VQ is designed to fit within existing CT-based workflows and infrastructure. CT:VQ offers relief from long-standing constraints associated with conventional nuclear VQ imaging, including radiotracer availability, workforce limitations and operational complexity. The European market represents a significant opportunity for advanced cardiothoracic imaging. With a population of more than 450 million, a highly developed hospital-based imaging infrastructure and an extensive installed base of CT scanners, the EU is well positioned for adoption of CT-based functional lung imaging. 4DMedical estimates that approximately 400,000 nuclear VQ scans are performed annually across the EU, underscoring the scale of clinical need. The CE Mark follows growing U.S. momentum for CT:VQ, which is now deployed at six leading academic medical centres: Stanford, Cleveland Clinic, University of Miami, UC San Diego Health, University of Chicago Medicine, and the recently announced initial deployment at Mayo Clinic. 4DMedical believes this early adoption by major U.S. institutions demonstrates strong interest in CT:VQ among leading radiology and pulmonary teams and provides a blueprint for expansion into Europe. 4DMedical said it is now advancing plans to expand commercial engagement across Europe and to work with leading hospitals and clinicians on adoption, evaluation and research initiatives for CT:VQ. CT:VQ is 4DMedical's proprietary ventilation-perfusion imaging solution that generates functional lung information from non-contrast CT scans. Built on the Company's patented XV Technology, CT:VQ is designed to provide quantitative ventilation and perfusion insights within familiar CT workflows, without requiring radiotracers.お知らせ • Mar 274DMedical Limited has filed a Follow-on Equity Offering in the amount of AUD 83.000002 million.4DMedical Limited has filed a Follow-on Equity Offering in the amount of AUD 83.000002 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 14,067,797 Price\Range: AUD 5.9 Discount Per Security: AUD 0.236 Transaction Features: Subsequent Direct Listingお知らせ • Jan 154DMedical Limited has completed a Follow-on Equity Offering in the amount of AUD 79.063503 million.4DMedical Limited has completed a Follow-on Equity Offering in the amount of AUD 79.063503 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 20,806,185 Price\Range: AUD 3.8 Discount Per Security: AUD 0.19お知らせ • Jan 02+ 1 more update4DMedical Limited Appoints Julian Sutton as Executive Director4DMedical Limited on January 2, 2026 announced the appointment of Julian Sutton Julian Sutton as Executive Director, effective January 2, 2026. Julian is an early investor in 4DMedical and has served as a Non-Executive Director since September 2017, developing deep expertise in the Company's technology, strategy, and commercial operations. Over this period, he has worked closely with the executive team on capital strategy, corporate governance, and investor relations, playing an instrumental role in securing funding to advance the Company's product development, regulatory and commercial objectives. Julian’s appointment to the executive team follows a period of significant commercial momentum for 4DMedical. With CT:VQ™ now FDA-cleared and actively deployed at leading U.S. academic medical centres, and a transformative global distribution agreement with Philips recently announced, the Company is well positioned for accelerated scale-up. This appointment formalises Julian’s strategic role at a pivotal inflection point in the Company's commercialisation. Julian Sutton’s term is set for three years with a three-month notice period.お知らせ • Sep 04+ 1 more update4DMedical Limited, Annual General Meeting, Oct 30, 20254DMedical Limited, Annual General Meeting, Oct 30, 2025.お知らせ • Feb 21+ 1 more update4DMedical Limited has completed a Follow-on Equity Offering in the amount of AUD 5.5 million.4DMedical Limited has completed a Follow-on Equity Offering in the amount of AUD 5.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 12,941,176 Price\Range: AUD 0.425 Discount Per Security: AUD 0.0255 Security Features: Attached Options Transaction Features: Subsequent Direct Listingお知らせ • Dec 204DMedical Limited Announces John Livingston Reverts to Non-Executive Director Position, Effective 1 January 20254DMedical Limited announced that Director John Livingston is to revert to a Non-Executive Director position with the Company, effective 1 January 2025. John's terms of appointment as a non-executive director will be on the same basis as other non-executive directors.お知らせ • Sep 244DMedical Limited, Annual General Meeting, Nov 20, 20244DMedical Limited, Annual General Meeting, Nov 20, 2024.お知らせ • Dec 164DMedical Limited has completed a Follow-on Equity Offering in the amount of AUD 35 million.4DMedical Limited has completed a Follow-on Equity Offering in the amount of AUD 35 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 44,303,797 Price\Range: AUD 0.79 Discount Per Security: AUD 0.0395 Security Features: Attached Options Transaction Features: Subsequent Direct Listingお知らせ • Dec 114DMedical Limited has filed a Follow-on Equity Offering in the amount of AUD 35 million.4DMedical Limited has filed a Follow-on Equity Offering in the amount of AUD 35 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 44,303,797 Price\Range: AUD 0.79 Discount Per Security: AUD 0.0395 Security Features: Attached Options Transaction Features: Subsequent Direct Listingお知らせ • Nov 234DMedical Receives U.S. FDA Clearance for CT LVAS Lung Function Scanning Software4DMedical has received FDA clearance for its CT-based ventilation product (CT LVAS(TM). CT LVAS, designed for use with computed Tomography scans, joins 4D Medical's XV LVAS(R) imaging software cleared for use with fluoroscopy In the United States. The FDA clearance for CT LVAS dovetails with the upcoming 4DMedical product, CT:VQ(TM). CT:VQ will enable quantitative perfusion (blood flow) data and visualizations to be extracted from CT scans. Standard CT images provide clinicians with structural detail about patients' lungs--from which they try to inferred information about disease and function. CT LVAS adds a wealth of data on lung performance on top of the structural detail of CT scans. This capability fills an information gap that enables radiologists to provide the objective, data-driven information that could materially inform diagnosis and treatment options. CT LVAS software processes existing CT scans using sophisticated algorithms derived from aerospace technology. These highly detailed reports include color-coded images of regional airflow and lung ventilation--overlayed on the patient's CT scan. CT LVAS uses a software-as-a-service model and requires no new capital equipment. Scans from existing CT equipment are uploaded for processing, where they are analyzed and returned to the radiologist as the Ventilation Report. CT LVAS measures lung ventilation in tens of thousands of locations in the lungs. The Regional Ventilation Visualizations provide region-specific ventilation at deep inspiratory breath-hold for a mid-coronal slice and threeaxial slices--Upper, Middle, and Lower. The regional ventilation data is quantified in lung volume change and regional lung ventilation heterogeneity.お知らせ • Nov 014DMedical Limited Announces Resignation of Evonne Collier as a Non-Executive Director, Chair of the Remuneration and Nomination Committee4DMedical Limited announced that Evonne Collier has resigned as a non-executive director, Chair of the Remuneration and Nomination Committee.お知らせ • Sep 254DMedical Limited Announces the Appointment of Geraldine Mcginty to the Board of Directors4DMedical Limited announced the appointment of Dr. Geraldine McGinty, MD, to the Company’s Board of Directors. Professor of Clinical Radiology and Population Health Sciences, and a certified radiologist practising at Weill Cornell Medical Center, Dr. McGinty is an accomplished academic, researcher, administrator and health care economist. In 2018, Dr. McGinty became the first woman elected as Chair of the American College of Radiology’s (ACR) board of Chancellors, making a significant contribution to the ACR through a reorganisation of its Data Science Institute, enabling greater board communication and diversity of opinion. The ACR is "The Voice of Radiology" in matters of legislation and regulation, and is responsible for guiding radiology reimbursement and coding issues, including relative value units, managed care, alternative payment models, and Medicare regulations. Prior to this, Dr. McGinty headed up the ACR’s Commission on Economics. The Commission’s work often is used as background material and evidence for ACR congressional and state legislative efforts as well as communications with the CMS (Centers for Medicare & Medicaid Services), policy makers, and other medical insurers. Her corporate governance experience includes serving on the Board of NextGen Healthcare, and as a Non-Executive Director with the Industrial Development Authority (IDA) of the Republic of Ireland, chairing its Audit, Risk and Finance Committee. Dr. McGinty is also a member of the Governing Authority of the University of Galway in Ireland. In her various leadership roles, Dr. McGinty has been a powerful and influential voice for women in medical imaging. She has also been instrumental in identifying and mentoring radiologists who push to address health disparities in research, advocacy efforts, artificial intelligence development, and medical student recruitment. Dr. McGinty is highly qualified in clinical practice and management, possessing both a medical degree from the National University of Ireland and a master’s degree in business administration from Columbia University. Dr. McGinty’s academic stature is reflected in her appointment as Professor of Clinical Radiology at Weill Cornell Medicine where she is concurrently Senior Associate Dean of Clinical Affairs. In 2017, Dr. McGinty was appointed as founding Academic Director for the Executive MBA and Masters in Healthcare Leadership program delivered jointly by Weill Cornell and the Cornell University SC Johnson School of Business, a role she performed until 2019. Dr. McGinty’s published work has focused on payment models for imaging, most recently a bundled payment for breast cancer screening. Recently she has focused on the impact of Artificial Intelligence on Medical Imaging and has spoken at the Turing Institute and to the WHO Focus Group on AI in Healthcare on this topic. As a member of the American Medical Association’s Relative Value Unit Update Committee from 2012- 2016, Dr. McGinty was instrumental in recommending reimbursement policy to Medicare, thereby impacting the economics of the entire U.S. healthcare delivery system. In addition, from 2015 to 2021, Dr. McGinty was Chief Strategy and Contracting Officer within Weill Cornell responsible for fee-for-service and value-based payment arrangements.お知らせ • Aug 294DMedical Limited, Annual General Meeting, Nov 02, 20234DMedical Limited, Annual General Meeting, Nov 02, 2023, at 10:00 AUS Eastern Standard Time.業績と収益の成長予測OTCPK:FDMD.F - アナリストの将来予測と過去の財務データ ( )AUD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数6/30/202855-8-28-336/30/202724-26-24-2136/30/20267-107-33-30212/31/20256-173-34-33N/A9/30/20256-101-35-34N/A6/30/20256-30-36-34N/A3/31/20256-27-34-32N/A12/31/20246-32-32-30N/A9/30/20245-34-32-31N/A6/30/20244-36-32-31N/A3/31/20242-33-33-32N/A12/31/20231-31-34-32N/A9/30/20231-31-29-28N/A6/30/20231-31-24-23N/A3/31/20231-30-19-18N/A12/31/20221-28-15-13N/A9/30/20221-26-22-19N/A6/30/20221-25-29-25N/A3/31/20221-23-28-24N/A12/31/20210-21-26-23N/A9/30/20210-21-21-19N/A6/30/20210-21-15-15N/A3/31/20210-26-16-15N/A12/31/20200-30-16-15N/A9/30/20201-26-12-11N/A6/30/20201-22-9-8N/A3/31/20202-16-8-7N/A12/31/20192-9-7-6N/A9/30/20191-8N/A-6N/A6/30/20191-6N/A-6N/A6/30/20181-4N/A-3N/A6/30/20171-4N/A-2N/A12/31/20150-1N/A-1N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: FDMD.F今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: FDMD.F今後 3 年間、利益が出ない状態が続くと予測されています。高成長収益: FDMD.F今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: FDMD.Fの収益 ( 85.3% ) US市場 ( 11.9% ) よりも速いペースで成長すると予測されています。高い収益成長: FDMD.Fの収益 ( 85.3% ) 20%よりも速いペースで成長すると予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: FDMD.F 3 年以内に赤字になると予測されています。成長企業の発掘7D1Y7D1Y7D1YHealthcare 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/31 19:35終値2026/05/26 00:00収益2025/12/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋4DMedical Limited 3 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。6 アナリスト機関John HesterBell PotterJohn CampbellJefferies LLCStephen BlaggJefferies LLC3 その他のアナリストを表示
お知らせ • Apr 014DMedical Limited has completed a Follow-on Equity Offering in the amount of AUD 83.000002 million.4DMedical Limited has completed a Follow-on Equity Offering in the amount of AUD 83.000002 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 14,067,797 Price\Range: AUD 5.9 Discount Per Security: AUD 0.236 Transaction Features: Subsequent Direct Listing
お知らせ • Mar 304Dmedical Limited Announces Commercial Launch of CT:VQ Imaging Technology in European Union4DMedical Limited announced that its latest imaging technology, CT:VQ has received CE Mark certification for commercial use in the European Union. 4DMedical will quickly launch commercial deployment of CT:VQ across one of the world's largest respiratory imaging markets. CT:VQ is the world's first and only non-contrast, ventilation-perfusion imaging technology, providing quantitative functional lung insights from routine non-contrast CT scans without the need for radiotracers or specialised nuclear medicine infrastructure. Pulmonary disease is fundamentally functional—defined by abnormalities in ventilation and perfusion—yet most routine imaging available to radiologists and pulmonologists remains purely structural. CT:VQ bridges that gap by generating ventilation and perfusion maps allowing clinicians to visualize regional lung function with the anatomical clarity of CT. For large medical institutions, CT:VQ is designed to fit within existing CT-based workflows and infrastructure. CT:VQ offers relief from long-standing constraints associated with conventional nuclear VQ imaging, including radiotracer availability, workforce limitations and operational complexity. The European market represents a significant opportunity for advanced cardiothoracic imaging. With a population of more than 450 million, a highly developed hospital-based imaging infrastructure and an extensive installed base of CT scanners, the EU is well positioned for adoption of CT-based functional lung imaging. 4DMedical estimates that approximately 400,000 nuclear VQ scans are performed annually across the EU, underscoring the scale of clinical need. The CE Mark follows growing U.S. momentum for CT:VQ, which is now deployed at six leading academic medical centres: Stanford, Cleveland Clinic, University of Miami, UC San Diego Health, University of Chicago Medicine, and the recently announced initial deployment at Mayo Clinic. 4DMedical believes this early adoption by major U.S. institutions demonstrates strong interest in CT:VQ among leading radiology and pulmonary teams and provides a blueprint for expansion into Europe. 4DMedical said it is now advancing plans to expand commercial engagement across Europe and to work with leading hospitals and clinicians on adoption, evaluation and research initiatives for CT:VQ. CT:VQ is 4DMedical's proprietary ventilation-perfusion imaging solution that generates functional lung information from non-contrast CT scans. Built on the Company's patented XV Technology, CT:VQ is designed to provide quantitative ventilation and perfusion insights within familiar CT workflows, without requiring radiotracers.
お知らせ • Mar 274DMedical Limited has filed a Follow-on Equity Offering in the amount of AUD 83.000002 million.4DMedical Limited has filed a Follow-on Equity Offering in the amount of AUD 83.000002 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 14,067,797 Price\Range: AUD 5.9 Discount Per Security: AUD 0.236 Transaction Features: Subsequent Direct Listing
お知らせ • Jan 154DMedical Limited has completed a Follow-on Equity Offering in the amount of AUD 79.063503 million.4DMedical Limited has completed a Follow-on Equity Offering in the amount of AUD 79.063503 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 20,806,185 Price\Range: AUD 3.8 Discount Per Security: AUD 0.19
お知らせ • Jan 02+ 1 more update4DMedical Limited Appoints Julian Sutton as Executive Director4DMedical Limited on January 2, 2026 announced the appointment of Julian Sutton Julian Sutton as Executive Director, effective January 2, 2026. Julian is an early investor in 4DMedical and has served as a Non-Executive Director since September 2017, developing deep expertise in the Company's technology, strategy, and commercial operations. Over this period, he has worked closely with the executive team on capital strategy, corporate governance, and investor relations, playing an instrumental role in securing funding to advance the Company's product development, regulatory and commercial objectives. Julian’s appointment to the executive team follows a period of significant commercial momentum for 4DMedical. With CT:VQ™ now FDA-cleared and actively deployed at leading U.S. academic medical centres, and a transformative global distribution agreement with Philips recently announced, the Company is well positioned for accelerated scale-up. This appointment formalises Julian’s strategic role at a pivotal inflection point in the Company's commercialisation. Julian Sutton’s term is set for three years with a three-month notice period.
お知らせ • Sep 04+ 1 more update4DMedical Limited, Annual General Meeting, Oct 30, 20254DMedical Limited, Annual General Meeting, Oct 30, 2025.
お知らせ • Feb 21+ 1 more update4DMedical Limited has completed a Follow-on Equity Offering in the amount of AUD 5.5 million.4DMedical Limited has completed a Follow-on Equity Offering in the amount of AUD 5.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 12,941,176 Price\Range: AUD 0.425 Discount Per Security: AUD 0.0255 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
お知らせ • Dec 204DMedical Limited Announces John Livingston Reverts to Non-Executive Director Position, Effective 1 January 20254DMedical Limited announced that Director John Livingston is to revert to a Non-Executive Director position with the Company, effective 1 January 2025. John's terms of appointment as a non-executive director will be on the same basis as other non-executive directors.
お知らせ • Sep 244DMedical Limited, Annual General Meeting, Nov 20, 20244DMedical Limited, Annual General Meeting, Nov 20, 2024.
お知らせ • Dec 164DMedical Limited has completed a Follow-on Equity Offering in the amount of AUD 35 million.4DMedical Limited has completed a Follow-on Equity Offering in the amount of AUD 35 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 44,303,797 Price\Range: AUD 0.79 Discount Per Security: AUD 0.0395 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
お知らせ • Dec 114DMedical Limited has filed a Follow-on Equity Offering in the amount of AUD 35 million.4DMedical Limited has filed a Follow-on Equity Offering in the amount of AUD 35 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 44,303,797 Price\Range: AUD 0.79 Discount Per Security: AUD 0.0395 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
お知らせ • Nov 234DMedical Receives U.S. FDA Clearance for CT LVAS Lung Function Scanning Software4DMedical has received FDA clearance for its CT-based ventilation product (CT LVAS(TM). CT LVAS, designed for use with computed Tomography scans, joins 4D Medical's XV LVAS(R) imaging software cleared for use with fluoroscopy In the United States. The FDA clearance for CT LVAS dovetails with the upcoming 4DMedical product, CT:VQ(TM). CT:VQ will enable quantitative perfusion (blood flow) data and visualizations to be extracted from CT scans. Standard CT images provide clinicians with structural detail about patients' lungs--from which they try to inferred information about disease and function. CT LVAS adds a wealth of data on lung performance on top of the structural detail of CT scans. This capability fills an information gap that enables radiologists to provide the objective, data-driven information that could materially inform diagnosis and treatment options. CT LVAS software processes existing CT scans using sophisticated algorithms derived from aerospace technology. These highly detailed reports include color-coded images of regional airflow and lung ventilation--overlayed on the patient's CT scan. CT LVAS uses a software-as-a-service model and requires no new capital equipment. Scans from existing CT equipment are uploaded for processing, where they are analyzed and returned to the radiologist as the Ventilation Report. CT LVAS measures lung ventilation in tens of thousands of locations in the lungs. The Regional Ventilation Visualizations provide region-specific ventilation at deep inspiratory breath-hold for a mid-coronal slice and threeaxial slices--Upper, Middle, and Lower. The regional ventilation data is quantified in lung volume change and regional lung ventilation heterogeneity.
お知らせ • Nov 014DMedical Limited Announces Resignation of Evonne Collier as a Non-Executive Director, Chair of the Remuneration and Nomination Committee4DMedical Limited announced that Evonne Collier has resigned as a non-executive director, Chair of the Remuneration and Nomination Committee.
お知らせ • Sep 254DMedical Limited Announces the Appointment of Geraldine Mcginty to the Board of Directors4DMedical Limited announced the appointment of Dr. Geraldine McGinty, MD, to the Company’s Board of Directors. Professor of Clinical Radiology and Population Health Sciences, and a certified radiologist practising at Weill Cornell Medical Center, Dr. McGinty is an accomplished academic, researcher, administrator and health care economist. In 2018, Dr. McGinty became the first woman elected as Chair of the American College of Radiology’s (ACR) board of Chancellors, making a significant contribution to the ACR through a reorganisation of its Data Science Institute, enabling greater board communication and diversity of opinion. The ACR is "The Voice of Radiology" in matters of legislation and regulation, and is responsible for guiding radiology reimbursement and coding issues, including relative value units, managed care, alternative payment models, and Medicare regulations. Prior to this, Dr. McGinty headed up the ACR’s Commission on Economics. The Commission’s work often is used as background material and evidence for ACR congressional and state legislative efforts as well as communications with the CMS (Centers for Medicare & Medicaid Services), policy makers, and other medical insurers. Her corporate governance experience includes serving on the Board of NextGen Healthcare, and as a Non-Executive Director with the Industrial Development Authority (IDA) of the Republic of Ireland, chairing its Audit, Risk and Finance Committee. Dr. McGinty is also a member of the Governing Authority of the University of Galway in Ireland. In her various leadership roles, Dr. McGinty has been a powerful and influential voice for women in medical imaging. She has also been instrumental in identifying and mentoring radiologists who push to address health disparities in research, advocacy efforts, artificial intelligence development, and medical student recruitment. Dr. McGinty is highly qualified in clinical practice and management, possessing both a medical degree from the National University of Ireland and a master’s degree in business administration from Columbia University. Dr. McGinty’s academic stature is reflected in her appointment as Professor of Clinical Radiology at Weill Cornell Medicine where she is concurrently Senior Associate Dean of Clinical Affairs. In 2017, Dr. McGinty was appointed as founding Academic Director for the Executive MBA and Masters in Healthcare Leadership program delivered jointly by Weill Cornell and the Cornell University SC Johnson School of Business, a role she performed until 2019. Dr. McGinty’s published work has focused on payment models for imaging, most recently a bundled payment for breast cancer screening. Recently she has focused on the impact of Artificial Intelligence on Medical Imaging and has spoken at the Turing Institute and to the WHO Focus Group on AI in Healthcare on this topic. As a member of the American Medical Association’s Relative Value Unit Update Committee from 2012- 2016, Dr. McGinty was instrumental in recommending reimbursement policy to Medicare, thereby impacting the economics of the entire U.S. healthcare delivery system. In addition, from 2015 to 2021, Dr. McGinty was Chief Strategy and Contracting Officer within Weill Cornell responsible for fee-for-service and value-based payment arrangements.
お知らせ • Aug 294DMedical Limited, Annual General Meeting, Nov 02, 20234DMedical Limited, Annual General Meeting, Nov 02, 2023, at 10:00 AUS Eastern Standard Time.